Eco Animal Health ( (GB:EAH) ) has issued an update.
ECO Animal Health Group has submitted a Marketing Authorisation Application to the European Medicines Agency for its ECOVAXXIN® Mycoplasma synoviae vaccine, marking a significant milestone in its vaccine development portfolio. This submission, slightly ahead of schedule, aligns with ECO’s commercialisation strategy and is expected to take 18 months for approval. The vaccine targets Mycoplasma synoviae, a significant poultry disease that causes economic losses due to reduced egg production and increased mortality. The company is also pursuing US marketing approval for the vaccine, anticipating simultaneous approval with Europe, and is working on a sister vaccine for Mycoplasma gallisepticum.
More about Eco Animal Health
ECO Animal Health is a global leader in the animal health industry, specializing in developing and marketing veterinary pharmaceuticals, particularly antibiotics and vaccines for pigs and poultry. The company is headquartered in the UK, operates in over 70 countries, and employs more than 200 people worldwide. Its flagship product, Aivlosin®, is a patented medication effective against respiratory and intestinal diseases in pigs and poultry.
YTD Price Performance: -16.20%
Average Trading Volume: 49,439
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £40.32M
For detailed information about EAH stock, go to TipRanks’ Stock Analysis page.